Ernexa Therapeutics Inc. Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Ernexa Therapeutics Inc. (ERNA) had Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year of $95.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $95.00K.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $143.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $26.00K.
- 2025-06-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $137.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $95.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $143.00K 10-Q · filed 2026-05-11 |
| 2025-09-30 | $26.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $137.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $206.00K 10-Q · filed 2025-05-07 |
| 2024-09-30 | $69.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $5.30M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $5.53M 10-Q · filed 2024-05-14 |
| 2023-09-30 | $932.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $1.06M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $203.00K 10-Q · filed 2023-05-11 |
| 2022-09-30 | $166.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $299.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $201.00K 10-Q · filed 2022-07-01 |
| 2021-09-30 | $183.88K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $361.32K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $428.88K 10-Q · filed 2021-05-17 |
| 2020-06-30 | $26.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $450.00K 10-Q · filed 2020-05-20 |
| 2019-09-30 | $165.00K 10-Q · filed 2019-11-01 |
| 2019-06-30 | $279.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | $334.00K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |